Compare Silicon Motion Technology Corporation American Depositary Shares (SIMO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Silicon Motion Technology Corporation American Depositary Shares vs Viatris Inc — how do they compare? Silicon Motion Technology Corporation American Depositary Shares trades at $207.79 (market cap $7.58B), while Viatris Inc trades at $17.68 (market cap $20.05B). The key difference: Viatris Inc is far larger — about 2.6× Silicon Motion Technology Corporation American Depositary Shares's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Silicon Motion Technology Corporation American Depositary Shares for 0 Days and Viatris Inc for 57 Days on average.
| SIMO | VTRS | |
|---|---|---|
Market Cap | $7.58B | $20.05B |
Volume | 1,236,983 | 8,682,135 |
Sector | Technology | Health |
52-Week High | $336.90 | $18.27 |
52-Week Low | $80.16 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $7.56B | $32.16B |
Dividend Yield | 0.9% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Silicon Motion (SIMO) trades at $246.63, down 0.13% on the day, with technical indicators showing neutral signals. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $2.43 versus $2.13, and revenue growth projected to reach $1.3B in 2026. Analyst sentiment remains overwhelmingly positive with 81% buy ratings and a consensus price target of $356.25, representing 44% upside potential from current levels.
The outlook for SIMO appears favorable given accelerating enterprise storage demand and AI infrastructure expansion. Key risks include semiconductor cycle volatility and competitive pressures in NAND controllers. With robust profitability metrics including 31.6% ROE and expanding margins, the stock offers growth exposure to the AI storage market, though investors should monitor execution on Q3 2026 earnings expectations of $3.3 EPS.
Viatris (VTRS) trades at $17.25, down 1.65% on the day, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported a net loss of $3.51 billion for 2025, though recent quarters have consistently beaten EPS estimates. Revenue remains stable around $14.3 billion, with a dividend of $0.12 declared for September 2026. The balance sheet shows a debt-to-asset ratio of 38.74% for 2025, with positive operating cash flow of $2.32 billion.
The outlook is mixed: analyst consensus is a Buy with a $22.17 price target, indicating 28% upside, supported by strong cash generation and pipeline progress. However, persistent net losses, high P/E ratio of 236.2, and competitive pressures in the generics market pose significant risks. Investor sentiment is cautiously optimistic, driven by earnings beats and strategic approvals like WAKIX in Japan.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Silicon Motion Technology Corporation American Depositary Shares
Silicon Motion Technology Corporation designs and develops NAND flash controllers for solid-state storage, with flagship SSD, eMMC, and UFS controller products, including its Ferri-branded automotive and industrial storage solutions, used by OEMs and NAND flash makers worldwide.
Read more on SIMO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
